EDDC Insights
TTC Considerations in Drug Discovery
The “Considerations in Drug Discovery” video series was produced by the Target Translation Consortium (TTC) with the hope of providing critical content in an easily understandable way to aspiring drug discoverers in Singapore and beyond. The less formal, ‘fireside chat’ format aims to present the insights drawn from experts in the field in a more relatable way.
The Importance of Target Validation | TTC Considerations in Drug Discovery Series
Preclinical cancer-target validation: How not to be wrong
Defining the Unmet Need | TTC Considerations in Drug Discovery Series
Cellular assays for Target Validation | TTC Considerations in Drug Discovery Series
In Vitro Biochemical and Biophysical Assays | TTC Considerations in Drug Discovery Series
A Medicinal Chemist’s Perspective | TTC Considerations in Drug Discovery Serie
Discovery and Development of Bio-Therapeutics | TTC Considerations in Drug Discovery SeriesTitle
Considerations in the Development of Cell Therapy | TTC Considerations in Drug Discovery Series
In Vivo Models in Drug Discovery | TTC Considerations in Drug Discovery Series
Navigating the Drug Discovery Journey
Carol Koh – Target Validation in Early Drug Discovery
Christophe Bodenreider – Hit Discovery & Validation Strategies
Joseph Cherian – A Hit is Not a Lead: A Medicinal Chemist’s Perspective
Klement Foo – Emerging Small Molecule Approaches
Lim Wan Hsin – Targeting RNA with Small Molecules
Wan Kah Fei – Exploring the Realm of Large Molecule Drugs: From Target to Lead Perspective
Snow Lee – New Horizons in Antibody Modalities for Targeted Therapy
Detlev Mennerich – Starting w/ the End in Mind 1: Boehringer Ingelheim’s Approach to External Innov.
Michael Wong – The Importance of Developing a Biomarker & Translational Strategy in Early Drug Discovery
Hannes Hentze – Preclinical In Vivo Studies
Kantharaj Ethirajulu – Preclinical Development
Katherine Wang – Singapore Therapeutics Development Review (STDR)
Drug Discovery: Past, Present and Future
EDDC’s Drug Discovery Symposium 2024 featured a line-up of esteemed speakers who shared their insights on how Drug Discovery has transformed, and will be transforming through past and future years.
Please note that the talk: “A Short Guidance on Success Factors in Drug Development” by Dr Andreas Wallnoefer, was not included as we did not have permission to record and make it publicly available.
Prof Alex Matter – The Challenges for Global Healthcare
Prof William Chin – Evolution of Drug Discovery – Finding Drugs Then and Now
Prof Jackie Hunter – How Bigger Data, Better Questions and AI-driven Tools are Changing Drug Discovery and Development
Navigating the Drug Frontier
ESMO 2024 – A Phase 1 Dose Escalation Study Of EBC-129
Your Own Prior Art: How to Avoid Shooting Yourself in the Foot!
Integrated IP Strategy for Platform Technologies and their Products | Mewburn Ellis, 25 Jan 2024
Quick Guide for Projects with Medicinal Chemistry Needs
Preclinical in vivo Studies for Drug Discovery and Development